| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CI-1040 | GDSC1000 | pan-cancer | AAC | -0.12 | 0.0007 |
| mRNA | AT-7519 | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0007 |
| mRNA | FQI-1 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.0008 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | ML311 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.0009 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.11 | 0.001 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.1 | 0.001 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.12 | 0.001 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.11 | 0.001 |